Breast Cancer
- ATLAS (2013): 10y vs. 5y tamoxifen in breast cancer
- EMILIA (2012): T-DM1 in metastatic breast cancer
- HERA (2005): Trastuzumab in breast cancer
- NSABP B-32 (2010): Sentinel LN biopsy in breast cancer
- STAR (2006): Tamoxifen vs. raloxifene in breast cancer prevention
Deep Vein Thrombosis
- CLOT (2003): LMWH vs. warfarin in cancer VTE
Lung Cancer
- Nivolumab vs docetaxel for Advanced NSCLC
- AZD9291 (osemertinib) for EGFR-inh resistant NSCLC
- Early Palliative Care (2010): Palliative care in NSCLC
- NLST (2011): CT vs. CXR in lung cancer screening
- PARAMOUNT (2013): Maintenance pemetrexed in lung cancer
Melanoma
- Pembrolizumab vs ipilimumab for Malignant Melanoma
- BRIM-3 (2011): Vemurafenib in BRAF V600+ melanoma
- CheckMate-003 (2012): Nivolumab in solid tumors
Prostate Cancer
- Enzalutamide maintenance after chemo NEJM 2012
- Enzalutamide in metastatic prostate cancer before chemo NEJM 2014
- Abiraterone and increased survival NEJM 2011
- Radium-223 and survival in prostate cancer NEJM 2013
- Sipuleucel-T immunotherapy for castrate-resistant prostrate cancer NEJM 2010
- Chemohormonal therapy in metastatic hormone-sensitive prostate cancer NEJM 2015
Renal Cell Carcinoma
- CheckMate-003 (2012): Nivolumab in solid tumors
- SWOG 8949 (2001): Cytoreductive nephrectomy in metastatic RCC
Colorectal Cancer
- MOSAIC trial (2009): Add adjuvant oxaliplatin to 5FU and Leucovorin for Stage II and III CRC
- FOLFOX Trial (2004) NEJM
- Capecitabine as adjuvant treatment for stage III CRC (2005) NEJM
- Subgroup Analysis 5FU + oxaliplatin for stage II or elderly (70-75 yrs)
- Identification of Lynch syndrome among patients with CRC (2012) JAMA
Palliative Care